Todd Franklin Watanabe - Jun 7, 2021 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
President and CEO, Director
Signature
/s/ Scott Burrows, as Attorney-in-Fact for Todd Franklin Watanabe
Stock symbol
ARQT
Transactions as of
Jun 7, 2021
Transactions value $
-$43,171
Form type
4
Date filed
6/9/2021, 04:35 PM
Previous filing
May 11, 2021
Next filing
Jun 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise $2.94K +1.75K +0.29% $1.68* 597K Jun 7, 2021 Direct F1, F2, F3
transaction ARQT Common Stock Sale -$46.1K -1.75K -0.29% $26.35 595K Jun 7, 2021 Direct F1, F2, F3
holding ARQT Common Stock 50K Jun 7, 2021 By LLC F4
holding ARQT Common Stock 17.9K Jun 7, 2021 By Trust F5
holding ARQT Common Stock 17.9K Jun 7, 2021 By Trust F6
holding ARQT Common Stock 125K Jun 7, 2021 By Trust F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (Right to Buy) Options Exercise $0 -1.75K -1.31% $0.00 131K Jun 7, 2021 Common Stock 1.75K $1.68 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
F3 Includes 1,006 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2021.
F4 The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5 The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F6 The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F7 The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F8 The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.